SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

SSgA Active Trust - SPDR S&P 500 ETF Trust

The SPY is experiencing heightened volatility as market participants react to recent geopolitical rhetoric from former President Trump, particularly concerning potential tariffs and comments about Greenland, which has sparked significant uncertainty among international allies. Community sentiment reflects apprehension about these developments, fueling discussions around a potential "Sell America" trade and a noticeable shift toward safe-haven assets like gold and silver amid broader economic and geopolitical concerns.

Invesco Capital Management LLC - Invesco QQQ Trust Series 1

QQQ is experiencing heightened volatility due to renewed global trade tensions, specifically concerning former President Trump's comments on Greenland and potential tariffs on European allies. The community is sharply divided, with bears anticipating a deeper market correction driven by geopolitical concerns and bond market stability, while bulls are aggressively buying dips, confident in a swift rebound and a potential policy reversal. This dynamic creates significant swings as participants debate the market's underlying strength amidst uncertainty.

Corvus Pharmaceuticals, Inc. engages in the development of immune modulator product candidates with the potential to treat solid cancers, T-cell lymphomas, autoimmune diseases, and infectious diseases. Its product pipeline includes B Cell Activator and Anti-CD73, Adenosine Production Inhibitor Anti-CD73, ITK Inhibitor, A2AR Inhibitor, Anti-CXCR2, and A2BR Inhibitor. The company was founded by Richard A. Miller, Peter A. Thompson, Joseph J. Buggy, and Erik Verner on January 27, 2014 and is headquartered in South San Francisco, CA.

Corvus Pharmaceuticals Inc

Corvus Pharmaceuticals is actively trending after reporting positive Phase 1 clinical trial data for its atopic dermatitis drug, soquelitinib, demonstrating strong efficacy and a favorable safety profile, particularly in treatment-resistant patients. The news has ignited significant community discussion around a potential short squeeze and sustained bullish momentum, with many anticipating future partnerships or a buyout. This early success in a large therapeutic market is generating considerable interest in the stock's long-term potential.

ImmunityBio, Inc. is a clinical stage immunotherapy company. It develops next generation therapies that drive immunogenic mechanisms for defeating cancers and infectious diseases. The company's immunotherapy platform activates both the innate and adaptive immune systems to create long term immunological memory. ImmunityBio was founded by Patrick Soon-Shiong in 2014 and is headquartered in San Diego, CA.

ImmunityBio Inc

ImmunityBio is trending following positive regulatory developments, as the FDA requested no new trials for its ANKTIVA cancer therapy's sBLA resubmission, signaling an accelerated path to market. The community is buzzing with optimism, anticipating substantial long-term growth driven by this key de-risking event and international market opportunities, while also discussing the potential for a significant short squeeze.

Trump Media & Technology Group Corp. engages in operating social media and in the technology business. Its brands include TRUTH Social, TMTG+ and TMTG News. The company was founded on March 28, 2024 and is headquartered in Sarasota, FL.

Trump Media & Technology Group Corp.

Trump Media & Technology Group Corp. is trending amid its announced record date for a new digital token initiative, which the community is discussing as a potential catalyst for a short squeeze. This development, coupled with ongoing geopolitical narratives and commentary surrounding its figurehead, fuels significant market speculation and contributes to its high volatility.

Bitcoin is the world's first decentralized cryptocurrency, created in 2009 by the pseudonymous Satoshi Nakamoto. It enables peer-to-peer electronic cash transactions without intermediaries like banks or governments, operating on a blockchain secured by Proof of Work mining and the SHA-256 cryptographic algorithm.   With a fixed supply cap of 21 million coins and programmatic halvings every four years that reduce miner rewards, Bitcoin is designed as a deflationary digital asset often called "digital gold." Its value stems from solving the double-spending problem without trusted intermediaries, creating the first truly scarce digital asset with censorship resistance and permissionless access that no government, corporation, or individual can control.  Bitcoin operates as a decentralized peer-to-peer network where transactions are recorded on a public ledger called the blockchain, distributed across thousands of computers globally. Transactions are grouped into blocks added approximately every 10 minutes through mining, where specialized computers compete to solve complex mathematical puzzles.   Bitcoin has achieved mainstream adoption through multiple vectors. The January 2024 SEC approval of 11 spot Bitcoin ETFs opened Bitcoin investment to traditional finance participants, and corporations like Strategy (formerly MicroStrategy) are using Bitcoin as a treasury reserve asset to protect against currency debasement, offering MSTR holders amplified exposure to Bitcoin.   The Bitcoin ecosystem continues to evolve with innovations like Ordinals, which emerged in January 2023 to enable NFT-like functionality directly on Bitcoin, and BRC-20 tokens, an experimental standard for creating fungible tokens using Ordinal inscriptions. BTCFi (Bitcoin Finance) represents emerging financial applications extending beyond Bitcoin's traditional role, with protocols like Babylon allowing Bitcoin holders to stake BTC to secure Proof of Stake chains.

Bitcoin

Bitcoin is trending due to significant market instability sparked by high-profile geopolitical rhetoric and broader financial concerns, including stress in Japan's bond market. The crypto community is intensely debating Bitcoin's status as a reliable hedge asset, noting substantial liquidations even as prominent institutions continue making large acquisitions. This dynamic creates a highly volatile environment and fuels ongoing discussion about its near-term trajectory.

Apple, Inc. engages in the design, manufacture, and sale of smartphones, personal computers, tablets, wearables and accessories, and other varieties of related services. It operates through the following geographical segments: Americas, Europe, Greater China, Japan, and Rest of Asia Pacific. The Americas segment includes North and South America. The Europe segment consists of European countries, as well as India, the Middle East, and Africa. The Greater China segment comprises China, Hong Kong, and Taiwan. The Rest of Asia Pacific segment includes Australia and Asian countries. Its products and services include iPhone, Mac, iPad, AirPods, Apple TV, Apple Watch, Beats products, AppleCare, iCloud, digital content stores, streaming, and licensing services. The company was founded by Steven Paul Jobs, Ronald Gerald Wayne, and Stephen G. Wozniak in April 1976 and is headquartered in Cupertino, CA.

Apple Inc

Apple (AAPL) is a trending topic amidst a prolonged downtrend and consistent selling pressure, defying recent positive reports of strong iPhone sales and market share gains, particularly in China. The community remains sharply divided, with many expressing frustration over its 'oversold' status and speculating on market manipulation, while others view the pullback as a significant buying opportunity ahead of its upcoming earnings report and potential clarifications on its AI strategy, including its partnership with Google Gemini.

Intel Corp. engages in the design, manufacture, and sale of computer products and technologies. It delivers computer, networking, data storage, and communications platforms. The firm operates through the following segments: Client Computing Group (CCG), Data Center and AI (DCAI), Network and Edge (NEX), Mobileye, Accelerated Computing Systems and Graphics (AXG), Intel Foundry Services (IFS), and All Other. The CCG segment consists of platforms designed for notebooks, 2-in-1 systems, desktops, tablets, phones, wireless and wired connectivity products, and mobile communication components. The DCAI segment delivers solutions to cloud service providers and enterprise customers, along with silicon devices for communications service providers and high-performance computing customers. The NEX segment offers computing system solutions from inflexible fixed-function hardware to general-purpose compute, acceleration, and networking devices running cloud native software on programmable hardware. The Mobileye segment develops driving assistance and self-driving solutions. The AXG segment provides products and technologies designed to help customers solve the toughest computational problems. Its products include CPUs for high-performance computing and GPUs targeted for a range of workloads and platforms, from gaming and content creation on client devices to delivering media and gaming in the cloud, and the most demanding high-performance computing and AI workloads on supercomputers. The IFS segment refers to full stack solutions created from the foundry industry ecosystem. The All Other segment represents results from other non-reportable segments and corporate-related charges. The company was founded by Robert Norton Noyce and Gordon Earle Moore on July 18, 1968 and is headquartered in Santa Clara, CA.

Intel Corp.

Intel Corp

Intel is trending following multiple analyst upgrades, renewed investor optimism from CES, and significant news of winning a U.S. SHIELD defense contract for advanced chip manufacturing. The community is actively debating the stock's ability to break through key resistance levels, with many believing the company is undervalued amidst the ongoing AI race and its strategic position in domestic chip production, despite some Wall Street caution ahead of upcoming earnings.

Novavax, Inc. Is a biotechnology company, which engages in the discovery, development, and commercialization of recombinant vaccines. The company was founded in 1987 and is headquartered in Gaithersburg, MD.

Novavax, Inc.

Novavax Inc

Novavax is trending following a key licensing agreement with Pfizer for its Matrix-M adjuvant technology, which the community views as a significant validation for the platform and a catalyst for potential future collaborations. Many are actively discussing the stock's high short interest, anticipating a substantial market move as the short thesis weakens. Despite this positive development, debates continue around management's overall strategy to maximize shareholder value and secure additional deals for its pipeline assets.

Netflix, Inc. engages in providing entertainment services. It also offers activities for leisure time, entertainment video, video gaming, and other sources of entertainment. It operates through the United States and International geographic segments. The company was founded by Marc Randolph and Wilmot Reed Hastings on August 29, 1997 and is headquartered in Los Gatos, CA.

Netflix Inc.

Netflix Inc

Netflix is a major talking point ahead of its earnings report, with community sentiment sharply divided on whether subscriber growth and ad-tier performance will spark a rally or a significant drop. The recent all-cash offer for Warner Bros. Discovery assets is a key discussion point, seen by some as a strategic play to secure the deal and by others as a potentially costly move impacting future debt. Traders are also noting the stock's oversold conditions, with some positioning for a rebound despite broader market uncertainties.

statis crypto Watchlist

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Short Interest in Disc Medicine, Inc. (NASDAQ:IRON) Grows By 53.8%

Disc Medicine, Inc. (NASDAQ:IRON - Get Free Report) was the recipient of a significant increase in short interest during the month of December. As of December 31st, there was short interest totaling...

<ul class="summary-bullets"><li>FDA is slated to decide on Disc Medicine's Bitopertin by February.&nbsp;</li><li>Approval for Lilly’s obesity pill is expected by April 10.</li><li>The FDA has also stalled the review of Sanofi’s Tzield for late-stage type 1 diabetes by more than a month over adverse event reports, Reuters said.</li></ul>Shares of Disc Medicine (IRON) fell 7% on Thursday after the U.S. Food and Drug Administration (FDA) reportedly delayed review of its drug Bitopertin despite choosing it for fast track review under a new voucher program.Reuters <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.reuters.com/sustainability/boards-policy-regulation/us-fda-delays-two-drug-reviews-new-voucher-program-after-safety-efficacy-2026-01-15/">reported</a> on Thursday, citing internal documents, that the FDA delayed the review of the company’s experimental drug for treatment of Erythropoietic Protoporphyria (EPP) after its scientists flagged safety and efficacy concerns. EPP is a rare, inherited metabolic disorder causing extreme sensitivity to sunlight and artificial light, leading to immediate, painful skin reactions like burning, redness, and swelling.The reviewers pushed the drug’s potential approval by two weeks to Feb. 10 as they examine whether it has abuse risks. The agency also has concerns if pain-free time in the sun is a statistically solid measure of efficacy or if other data can justify approval, the report said.Disc Medicine’s Bitopertin is one of the 18 drugs to currently have been tapped for fast review by the FDA under its Commissioner's National Priority Voucher program announced in June 2025. The program aims to reduce FDA assessment time to one to two months from the standard 10 to 12 months.<h2 class="st-heading-2">Sanofi Faces Longer Delay</h2>The FDA has also stalled the review of Sanofi’s (SNY) Tzield for late-stage type 1 diabetes by more than a month over adverse event reports, Reuters said.The agency is considering the death of a patient while taking the drug and also evaluating two reports related to seizure and blood clotting. The agency was initially slated to decide on the application by Nov. 21.<h2 class="st-heading-2">Lilly’s Weight-Loss Drug Approval Now Slated For Q2</h2>Other drugs to face delays beyond the original target date include Boehringer Ingelheim's zongertinib for lung cancer and Eli Lilly’s (LLY) weight-loss pill. While zongertinib approval is now expected in mid-February, approval for Lilly’s obesity pill is expected by April 10, later than its initial first quarter (Q1) estimate, Reuters said.<a href="https://stocktwits.com/symbol/LLY">LLY shares</a> traded 4% lower at the time of writing while <a href="https://stocktwits.com/symbol/SNY">SNY shares</a> fell 1%.According to Reuters, at least seven drugs selected for priority review have started the approval process. While most of the reviews for the drugs selected for the program are slated to start this year, others are scheduled for 2027 and 2028.Only one antibiotic drug has been approved under the program as of date called Augmentin XR.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment around IRON and SNY stocks trended in the ‘Neutral’ territory at the time of writing. Retail sentiment around LLY, however, rose from ‘bullish’ to ‘extremely bullish’ over the past 24 hours.A Stocktwits user dismissed the delay report as a “short term hiccup.”<stembedurl>https://www.stocktwits.com/wwmeinc/message/641906137</stembedurl>Another opined that the selloff in IRON shares is a buying opportunity.<stembedurl>https://www.stocktwits.com/StockBraker/message/641896960</stembedurl><a href="https://stocktwits.com/symbol/IRON">IRON stock</a> has gained 18% over the past 12 months. &nbsp;&nbsp;Read More: <a href="https://stocktwits.com/news-articles/markets/equity/ford-contemplating-deal-with-chinese-rival-byd-as-it-seeks-to-scale-hybrids-report/cmU1pwgR4JJ">Ford Contemplating Deal With Chinese Rival BYD As It Seeks To Scale Hybrids: Report</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the Disc Medicine logo is seen displayed on a smartphone screen. (Photo Illustration by Thomas Fuller/SOPA Images/LightRocket via Getty Images)

Disc Medicine, Sanofi, Eli Lilly Shares Slip On Reports Of FDA Increasing Review Time For Drugs Granted Priority Review Vouchers

Reuters reported on Thursday that the FDA delayed the review of Disc Medicine’s experimental drug for the treatment of Erythropoietic Protoporphyria (EPP) after its scientists flagged safety and efficacy concerns.

Equity

Reuters reported on Thursday that the FDA delayed the review of Disc Medicine’s experimental drug for the treatment of Erythropoietic Protoporphyria (EPP) after its scientists flagged safety and efficacy concerns.


Disc Medicine (NASDAQ:IRON) Shares Gap Down - Should You Sell?

Disc Medicine (NASDAQ:IRON) Shares Gap Down - What's Next...

Disc Medicine (NASDAQ:IRON) Insider Rahul Khara Sells 6,500 Shares

Disc Medicine, Inc. (NASDAQ:IRON - Get Free Report) insider Rahul Khara sold 6,500 shares of Disc Medicine stock in a transaction that occurred on Friday, January 2nd. The shares were sold at an...

Disc Medicine (NASDAQ:IRON) Insider Sells $511,485.00 in Stock

Disc Medicine, Inc. (NASDAQ:IRON - Get Free Report) insider Rahul Khara sold 6,500 shares of the company's stock in a transaction dated Friday, January 2nd. The shares were sold at an average price...

Disc Medicine, Inc. (NASDAQ:IRON) Receives Consensus Rating of "Moderate Buy" from Brokerages

Shares of Disc Medicine, Inc. (NASDAQ:IRON - Get Free Report) have been assigned an average rating of "Moderate Buy" from the thirteen brokerages that are presently covering the company, Marketbeat...

<ul class="summary-bullets"><li>Disc Medicine management said earlier this month that its application seeking approval for Bitopertin has officially been accepted for review on schedule.&nbsp;</li><li>Wall Street analysts dismissed the media report hinting at approval delays and termed the share drop as overblown.&nbsp;</li><li>Disc Medicine is hopeful for an approval of the drug by the end of January 2026.</li></ul>Shares of Disc Medicine (<a href="https://stocktwits.com/symbol/IRON">IRON</a>) plunged 12% on Friday after a report flagged concerns pertaining to the U.S. Food and Drug Administration’s speedy approval of the company’s blood disorder drug Bitopertin.Disk Medicine’s Biopertin for the treatment of Erythropoietic Protoporphyria (EPP) is one of the 18 drugs to currently have been tapped for fast review by the FDA under its Commissioner's National Priority Voucher program. The Commissioner's National Priority Voucher program, announced in June, aims to reduce FDA assessment times to one to two months from the standard 10 to 12 months.However, Stat News <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.statnews.com/2025/12/19/fda-voucher-program-political-interference/">reported</a> on Friday, citing government officials, that high-level FDA officials have been involved in every part of the new program involving the vouchers. The political pressure is creating “uncomfortable situations” for career scientists at the FDA, the report said.The report dragged down investor sentiment and hopes for an expedited approval of Bitopertin as the report also noted that FDA senior official Vinay Prasad raised doubts about the drug’s effectiveness.<h2 class="st-heading-2">Wall Street Dismisses Concerns</h2>Jefferies analyst Roger Song, however, termed the share drop a “stock overreaction”. Song said that while the priority voucher program's timeline may be under pressure with increasing demand, the firm remains confident on Bitopertin's approval in EPP under the program, based on robust efficacy and safety data and to-date review experience.TD Cowen also maintained its ‘Buy’ rating on the shares and said the firm believes skepticism on the program’s path is overblown. Disc's management remains confident, it noted, and added that the firm's confidence in accelerated approval remains high.BMO Capital said that it had discussions with Disc Medicine’s management which highlighted a lack of interactions with senior official Prasad but robust active dialogue with the FDA. While Prasad may have speculated efficacy concerns related to Bitopertin, these have not been communicated to Disc, and no clear concerning questions around efficacy have been raised, BMO added. Some procedural questions have been asked by FDA in trying to understand the Bitopertin data package and how it may translate to clinical benefit, it said. The firm has an ‘Outperform’ rating on the shares with a price target of $120.<h2 class="st-heading-2">Management Takeaway</h2>Disc Medicine management said earlier this month that its application seeking approval for Bitopertin has officially been accepted for review on schedule and expressed hopes for potential launch by the end of January 2026, consistent with the 1-2 month timeline for drugs which receive the priority voucher.“Our commercialization efforts have been accelerated significantly and we are well on our way to launch readiness,” the company said.The company submitted its application for approval in patients aged 12 years and older with EPP on September 29. Erythropoietic Protoporphyria (EPP) is a rare, inherited metabolic disorder causing extreme sensitivity to sunlight (phototoxicity), leading to immediate, painful skin reactions like burning, tingling, redness, and swelling, due to the buildup of protoporphyrin in red blood cells from an enzyme deficiency.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment around IRON stayed within the ‘bearish’ territory while message volume rose from ‘low’ to ‘high’ levels.IRON stock has gained about 26% this year.Also See: <a href="https://stocktwits.com/news-articles/markets/equity/nvidia-intel-shares-jump-after-us-antitrust-agencies-clear-5-billion-deal/cLe0d1gREtc">Nvidia, Intel Shares Jump After US Antitrust Agencies Clear $5B Deal That Deepens Their Chip Partnership</a>For updates and corrections, email newsroom[at]stocktwits[dot]com

Disc Medicine Stock Slides After FDA Fast-Track Approval Doubts Surface — Wall Street Calls It An ‘Overreaction’

Stat News on Friday raised concerns for Biopertin’s expedited approval under the FDA Commissioner's National Priority Voucher program. 

Disc Medicine Enters Oversold Territory (IRON)

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a...

Disc Medicine (NASDAQ:IRON) Shares Down 9% After Insider Selling

Disc Medicine (NASDAQ:IRON) Shares Down 9% Following Insider Selling...

Disc Medicine (NASDAQ:IRON) Director Kevin Bitterman Sells 754 Shares

Disc Medicine, Inc. (NASDAQ:IRON - Get Free Report) Director Kevin Bitterman sold 754 shares of the business's stock in a transaction that occurred on Wednesday, December 17th. The shares were sold...

Disc Medicine, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovery, development, and commercialization of treatments for hematologic diseases. It assembles a portfolio of clinical and preclinical product candidates that aim to modify fundamental biological pathways associated with the formation and function of red blood cells, specifically heme biosynthesis and iron homeostasis. The company was founded in October 2017 and is headquartered in Watertown, MA.

IRON
Disc Medicine Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest IRON News

IRONDisc Medicine Inc